C
Catherine Rhuda
Researcher at Harvard University
Publications - 3
Citations - 695
Catherine Rhuda is an academic researcher from Harvard University. The author has contributed to research in topics: Transplantation & Haematopoiesis. The author has an hindex of 3, co-authored 3 publications receiving 684 citations. Previous affiliations of Catherine Rhuda include Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte–macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
Robert J. Soiffer,Thomas R. Lynch,Martin C. Mihm,Kenneth Jung,Catherine Rhuda,Jan C. Schmollinger,F S Hodi,L Liebster,P Lam,Steven J. Mentzer,Samuel Singer,Kenneth K. Tanabe,Cosimi Ab,Rosemary B. Duda,Arthur J. Sober,Atul K. Bhan,John F. Daley,Donna Neuberg,Gareth Parry,J Rokovich,L Richards,J Drayer,Anton Berns,Shirley M. Clift,Lawrence K. Cohen,Richard C. Mulligan,Glenn Dranoff +26 more
TL;DR: It is demonstrated that vaccination with irradiated autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor stimulates potent antitumor immunity in humans with metastatic melanoma.
Journal Article
A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
Michael L. Grossbard,Pratik S. Multani,Arnold S. Freedman,Steven J. O'Day,John G. Gribben,Catherine Rhuda,Donna Neuberg,Lee M. Nadler +7 more
TL;DR: It is demonstrated that Anti-B4-bR can be administered safely to patients as adjuvant therapy early after ABMT for B-cell NHL, and the toxicities are tolerable and reversible.
Journal ArticleDOI
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Dose Intensification With Granulocyte Colony-Stimulating Factor Markedly Depletes Stem Cell Reserve for Autologous Bone Marrow Transplantation
Arnold S. Freedman,Donna Neuberg,Donna Neuberg,Peter Mauch,Peter Mauch,John G. Gribben,John G. Gribben,Robert J. Soiffer,Robert J. Soiffer,Kenneth C. Anderson,Kenneth C. Anderson,Michael J. Robertson,Michael J. Robertson,David C. Fisher,David C. Fisher,Robert L. Schlossman,Robert L. Schlossman,Mary Kroon,Mary Kroon,Catherine Rhuda,Catherine Rhuda,Caroline Kuhlman,Caroline Kuhlman,Jerome Ritz,Jerome Ritz,Lee M. Nadler,Lee M. Nadler +26 more
TL;DR: In patients with previously untreated advanced follicular lymphoma, trilineage hematopoietic engraftment was compared in two sequential trials of induction therapy and dose intensified chemotherapy and G-CSF recruited stem cells into a proliferative phase and that G- CSF allowed retreatment at a time when stem cells were susceptible to damage by cytotoxic therapy.